Sunday, July 12, 2020

Biocon’s biosimilar for treating Covid-19: Patients responded positively, says Kiran Mazumdar-Shaw

The Drug Controller General of India (DGCI) has permitted the
Bengaluru-headquartered drug maker to market Itolizumab (ALZUMab)
injection 25 mg/5 mL solution for emergency use in India for treating
cytokine release syndrome (CRS) in moderate to severe ARDS (acute
respiratory distress syndrome) Covid patients.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocons-biosimilar-for-treating-covid-19-patients-responded-positively-says-kiran-mazumdar-shaw/articleshow/76920970.cms
Posted by at

1 comment:

  1. Maya AaliyahJuly 12, 2020 at 4:23 AM

    Good information. Thanks for sharing. If you want to know more about stock market related topics then visit
    Simple Moving Average
    Scalp trading
    Commodity trading

    ReplyDelete

Subscribe to: Post Comments (Atom)